PETMED EXPRESS INC
Close on Oct 19, 2026
- Market cap
- $24.93M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $41.00M | $-0.28 | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 2, 2026 | During market hours | $42.80M | $-0.19 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 16, 2025 | Before market open | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 10, 2025 | During market hours | $53.00M | $-0.03 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $59.60M | $0.11 | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | $68.00M | $0.18 | – |
| Q4 FY2024 Ended Mar 31, 2024 | Apr 15, 2024 | Before market open | $65.30M | $-0.10 | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 8, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Sep 30, 2023 | Oct 30, 2023 | During market hours | – | – | – |
| Q1 FY2024 Ended Jun 30, 2023 | Jul 31, 2023 | During market hours | – | – | – |
Press releases
Announcements Petmed Express filed with the SEC
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMeds Extends Existing Shareholder Rights Plan
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq
Results of operations · Listing notice · EX-99.1 to Form 8-K
PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Files Form 10-K for Fiscal 2025
Results of operations · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Management Changes
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
Results of operations · EX-99 to Form 8-K
PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Third Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMeds® Adopts Limited Duration Shareholder Rights Plan
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Second Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Fiscal 2025 First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Appointment of Doug Krulik as Chief Accounting Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement.
Results of operations · EX-99.1 to Form 8-K
PetMeds® Announces Selected Preliminary Third Quarter Financial Results
Results of operations · Prior financials no longer reliable · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Its Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
PetMeds® Announces Its First Quarter Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
QUARTER AND YEAR ENDED MARCH 31, 2023
Results of operations · EX-99.1 to Form 8-K
PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds ® Appoints Sandra Y. Campos to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
With the transaction’s closing, the consumer-facing PetCareRx e-commerce operation and the brand will continue to run separately. Customers will continue to enjoy the same world-class service and e-commerce experience, supported by a more efficient distribution network and broader product selection.
Regulation FD disclosure · Other events · EX-99 to Form 8-K
PetMeds® Announces Its Third Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Analyst Day January 2023 NASDAQ: PETS
Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds ® to Acquire PetCareRx
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Announces Its Second Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
QUARTER ENDED JUNE 30, 2022
Results of operations · EX-99.1 to Form 8-K
PetMeds® Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds® Hires Christine Chambers as Chief Financial Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
PetMeds ® To Announce Its First Quarter Financial Results On July 25, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
QUARTER AND YEAD ENDED MARCH 31, 2022
Results of operations · EX-99.1 to Form 8-K